HERA-LIGAND
Apogenix AG
| Research |
OneLook
Acronym Finder
|
| Serial Number | 79262795 |
| Registration Number | 6144135 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Law Office Assigned | L50 |
| Employee Name | TWOHIG, SHANNON MARIE |
Timeline
| 2019-05-08 | Application Filed |
| 2019-07-23 | Location: TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED |
| 2019-08-20 | Status: Live/Pending |
| 2019-09-06 | Transaction Date |
| 2020-09-08 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Apogenix AG |
| Entity Statement | Stock Corporation |
| Address | Im Neuenheimer Feld 584 69120 Heidelberg DE |
| Legal Entity Type | |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 42 |
| U.S. Codes: | 100,101 |
| International Codes: | 44 |
| U.S. Codes: | 100,101 |
| Type Code | Type |
|---|---|
| GS0421 | Scientific services and research in the field of oncology and immunology relating to fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific and technological services in the field of oncology and immunology relating to fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; consulting and information relating to the aforementioned services, included in this class |
| GS0421 | Scientific services, namely, scientific and pharmaceutical research in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific and technological services, namely, protein design and protein engineering in the field of oncology and immunology relating to trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety; scientific consulting services in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety and providing scientific information in the field of protein design and protein engineering regarding trivalent or hexavalent fusion proteins with tumor necrosis factor superfamily (TNF-SF) moiety |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2019-07-11 | 1 REPR M: |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-07-16 | 2 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2019-07-20 | 3 MAFR O:Outgoing Correspondence |
| ASSIGNED TO EXAMINER | 2019-07-22 | 4 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2019-07-23 | 5 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2019-07-24 | 6 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2019-08-20 | 7 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2019-08-21 | 8 RFCS P: |
| REFUSAL PROCESSED BY IB | 2019-09-06 | 9 RFNT P: |
| TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2020-02-04 | 10 REAP I:Incoming Correspondence |
| ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2020-02-04 | 11 ARAA I:Incoming Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2020-02-07 | 12 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2020-02-07 | 13 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2020-02-07 | 14 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2020-02-12 | 15 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2020-03-04 | 16 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2020-03-24 | 17 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2020-03-24 | 18 NPUB E:E-Mail |
| EXTENSION OF TIME TO OPPOSE RECEIVED | 2020-04-21 | 19 ETOF T:TTAB Proceeding |
| TEAS POST PUBLICATION AMENDMENT RECEIVED | 2020-05-28 | 20 EPPA I:Incoming Correspondence |
| ASSIGNED TO PETITION STAFF | 2020-06-23 | 21 APET A:Allowance for Publication |
| CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED | 2020-06-23 | 22 CHPB I:Incoming Correspondence |
| EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | 2020-08-02 | 23 ETOP T:TTAB Proceeding |
| REGISTERED-PRINCIPAL REGISTER | 2020-09-08 | 24 R.PR A:Allowance for Publication |
| FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | 2020-12-08 | 25 FICR P: |
| FINAL DISPOSITION PROCESSED | 2020-12-28 | 26 FIMP P: |
| FINAL DISPOSITION NOTICE SENT TO IB | 2020-12-28 | 27 FICS P: |
| FINAL DECISION TRANSACTION PROCESSED BY IB | 2021-01-15 | 28 FINO P: |
| NEW REPRESENTATIVE AT IB RECEIVED | 2021-12-24 | 29 NREP P: |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 